Strong R&D infrastructure but slow to market - Senior Scientist Lupin Employee Review

2.0
May 19, 2026
Recommend
CEO approval
Business outlook

Pros

Good infrastructure in R&D, manufacturing, robust compliance set up.

Cons

Compared to Pharma biologics seems weak. Long timelines from inception to market delivery. In comparison, other Indian biosimilar sponsors have gone far ahead.

Explore other reviews about Lupin

5.0
May 28, 2024
Recommend
CEO approval
Business outlook

Pros

Great work place, plenty of room for growth

Cons

No significant drawbacks, great place to work

4.0
Jun 12, 2026
Recommend
CEO approval
Business outlook

Pros

Very good pay overall here

Cons

Not many to report actually

See reviews by: Helpful|Rating|Date|All